Literature DB >> 25511313

Bone: Will breast cancer chemoprevention stand on 'solid bone'?

Larry J Suva1, Issam Makhoul1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25511313      PMCID： PMC4334702          DOI： 10.1038/nrendo.2014.220

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  6 in total

1.  Exemestane for breast-cancer prevention in postmenopausal women.

Authors:  Paul E Goss; James N Ingle; José E Alés-Martínez; Angela M Cheung; Rowan T Chlebowski; Jean Wactawski-Wende; Anne McTiernan; John Robbins; Karen C Johnson; Lisa W Martin; Eric Winquist; Gloria E Sarto; Judy E Garber; Carol J Fabian; Pascal Pujol; Elizabeth Maunsell; Patricia Farmer; Karen A Gelmon; Dongsheng Tu; Harriet Richardson
Journal:  N Engl J Med       Date:  2011-06-04       Impact factor: 91.245

2.  Breast cancer chemoprevention: little progress in practice?

Authors:  David A Cameron
Journal:  Lancet       Date:  2013-12-12       Impact factor: 79.321

3.  American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

Authors:  Catherine H Van Poznak; Sarah Temin; Gary C Yee; Nora A Janjan; William E Barlow; J Sybil Biermann; Linda D Bosserman; Cindy Geoghegan; Bruce E Hillner; Richard L Theriault; Dan S Zuckerman; Jamie H Von Roenn
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

4.  Intent-to-Treat vs. Non-Intent-to-Treat Analyses under Treatment Non-Adherence in Mental Health Randomized Trials.

Authors:  Thomas R Ten Have; Sharon-Lise T Normand; Sue M Marcus; C Hendricks Brown; Philip Lavori; Naihua Duan
Journal:  Psychiatr Ann       Date:  2008-12

5.  Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.

Authors:  Jack Cuzick; Ivana Sestak; John F Forbes; Mitch Dowsett; Jill Knox; Simon Cawthorn; Christobel Saunders; Nicola Roche; Robert E Mansel; Gunter von Minckwitz; Bernardo Bonanni; Tiina Palva; Anthony Howell
Journal:  Lancet       Date:  2013-12-12       Impact factor: 79.321

6.  Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.

Authors:  Ivana Sestak; Shalini Singh; Jack Cuzick; Glen M Blake; Rajesh Patel; Fatma Gossiel; Rob Coleman; Mitch Dowsett; John F Forbes; Anthony Howell; Richard Eastell
Journal:  Lancet Oncol       Date:  2014-11-11       Impact factor: 41.316
  6 in total
  1 in total

Review 1.  The best of both worlds - managing the cancer, saving the bone.

Authors:  Issam Makhoul; Corey O Montgomery; Dana Gaddy; Larry J Suva
Journal:  Nat Rev Endocrinol       Date:  2015-10-27       Impact factor: 43.330
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.